Search Results for: SRPT
Here are the biotech companies with exposure to experimental vaccines whose shares saw the biggest boost from this past week's coronavirus news.
Published:
Sarepta Therapeutics received a favorable rating from Merrill Lynch, and as a result the stock soared in Tuesday's trading session.
Published:
Last Updated:
Thursday's top analyst upgrades, downgrades and initiations include Ally FInancial, Apple, Automatic Data Processing, Brocade Communications, Level 3 Communications and Tyco International.
Published:
Here are some biotech companies with exposure to experimental vaccines whose shares are seeing the biggest boost from the latest coronavirus news.
Published:
Once again, concerns over European debt is sending stocks tumbling. The Dow is down 0.61%, the Nasdaq is down 0.39% and the S&P 500 is down 0.62%. There were a ton of high volume winners and losers...
Published:
Last Updated:
Tekmira Pharmaceuticals downgrade also drags down Sarepta Therapeutics and BioCryst Pharmaceuticals.
Published:
24/7 Wall St. has collected three big FDA decisions coming up in February and added some color, along with the trading range and price target.
Published:
Last Updated:
Sarepta announced a public offering of more than 3 million shares of its common stock at a price to the public of $39.00 per share, with a value of up to more than $145 million.
Published:
News has hit of the first confirmed Ebola case in the United States. Companies involved in potential drugs for Ebola have seen their shares pop.
Published:
Making the move for a secondary offering after a stock has jumped massively is one way for companies to literally cash in on their recent success.
Published:
Last Updated:
Friday afternoon's analyst upgrades and downgrades included BigCommerce, Citrix, GlaxoSmithKline, Nikola, Regeneron, Shake Shack and more.
Published:
These are the top analyst upgrades, downgrades and initiations covered by 24/7 Wall St. for Wednesday, September 24, 2014.
Published:
Recently we have seen a surge in Ebola-related stocks across the board, but Friday trading brought a mixed view for this group.
Published:
With the CDC not releasing enough data on the patient, there could be an opportunity for traders on both sides of the Ebola story.
Published:
Fears of Ebola have plagued the United States since late September, and some biotech companies have capitalized on this fear.
Published: